🇺🇸 AG0301-COVID19 in United States

5 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 5

Most-reported reactions

1. Cough — 1 report (20%)
2. Drug Ineffective — 1 report (20%)
3. Headache — 1 report (20%)
4. Pain — 1 report (20%)
5. Productive Cough — 1 report (20%)

Source database →

Frequently asked questions

Is AG0301-COVID19 approved in United States?

AG0301-COVID19 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for AG0301-COVID19 in United States?

AnGes, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.